Dr Maureen Merrifield has joined Pharmatech Associates and will the company’s clinical and regulatory affairs.

Dr Maureen Merrifield will be responsible for oversight & management of all clinical and regulatory strategy & support activities relating to regulatory submissions on a global basis.

“We are extremely pleased to welcome Dr. Merrifield to our team of professional consultants,” said Warren Baker, chief executive officer, Pharmatech Associates. “Her outstanding leadership skills and strong experience in regulatory surveillance are important assets that aid in resolving the clinical development issues confronting our clients.”

In over a dozen years in the biotechnology and pharmaceutical industry, Dr. Merrifield has developed regulatory pathways to market for unique and complex investigational products. Her work supports early and late-stage drug development in therapeutic areas such as cell/gene therapy, peptides, monoclonal antibodies, vaccines, small molecule, blood/tissue therapy, and combination products.

Dr. Merrifield holds a Ph.D., and a bachelor of science in chemistry, with honors, from Western University in Ontario, Canada.